MRK · Merck & Co. Inc.
AI read · Neutral
The AI's read
The BRUNELLO topline shows Merck's candidate produced vision improvement similar to Roche's Lucentis at 52 weeks, which supports Merck's retinal drug program. The report also notes higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and treatment discontinuations with remigromig, which raises safety questions that need further detail before the news can be judged clearly positive.